Non-Hodgkin Lymphoma Treatment Market is poised to showcase a significant CAGR during the forecast period.

Non-Hodgkin lymphoma is a cancer that affects the white blood cells. This reduces the immunity of the patient. This type of cancer is severe which has encouraged an extensive research for developing treatment method that are effective and efficient. This has increased the number of investments made for its research, thereby propelling the non-hodgkin lymphoma treatment market growth. Additionally, the rising awareness regarding the disease, bolstered drug pipeline for the disease treatment and improvements in the diagnostic methodologies for detecting lymphoma and the rising occurrence of NHL, thereby propelling the market growth. 
As per the American Cancer Society, NHL is prevalent in the United States that covers over 5% of all the cancers. Radiation therapy is used for treating NHL in its earlier stages. Radiation therapy, along with chemotherapy, is used for treating advanced lymphomas and in case of a widespread HNL, palliative radiotherapy is primarily preferred. Furthermore, as per the Leukemia and Lymphoma Society, 2019, over 80,000 new lymphoma cases were registered, out of which over 74,000 were NHL cases. Additionally, it is projected that over 870,000 people in the United are identified with lymphoma. Moreover, strategic collaborations for cancer therapeutics has bolstered the market growth. For example, Amgen Inc., in 2015, partnered with Merck & CO. Inc. to bolster a cancer immunotherapy phase 3 study, investigating Blincyto in combination with Keytruda in people with Diffuse Large B-Cell Lymphoma, a more prevalent NHL.     

Non-Hodgkin Lymphoma Treatment Market

Market Segmentation:

By Therapy Type
•    Radiation Therapy
•    Chemotherapy 
•    Targeted Therapy 
•    Others
By Drug Type
•    Opdivo
•    Adcetris
•    Rituxan
•    Imbruvica
•    Revlimid
•    Keytruda
•    Other Drugs
By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

The market is fragmented into therapy type, drug type and region. The therapy type segment is categorised into radiation therapy, chemotherapy, targeted therapy and other therapy types. The radiation therapy segment is predicted to hold the largest non-hodgkin lymphoma treatment market share owing to its rising adoption across the world and this therapy has lesser side effects than chemotherapy. The drug type segment is categorised into Opdivo, Adcetris, Rituxan, Imbruvica, Revlimid, Keytruda and others. The Revlimid segment is predicted to lead the market and this is owing to the increased sales in 2018 with its effectivity in treating cancer. 

Regional Analysis:

The Asia Pacific region is predicted to lead the market during the forecast period due to factors like increased access to healthcare facilities and rising occurrence of NHL. As per the research conducted in 2018, it was projected that the rate of incidence of NHL in China was over 7 per 100,000 annually.  AS the prevalence of NHL is increasing each year, many key players are heavily investing in developing advanced drug therapies for meeting the increased demand. Furthermore, the government bodies of the region are constantly undertaking initiatives for creating awareness regarding NHL and its treatment which shall augment the market growth. 

Competitive Landscape:                            

Some of the prominent players of the market are Bristol-Myers Squibb Company, Celgene Corporation, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Seattle Genetics Inc., Takeda Pharmaceutical Company Ltd., Johnson & Johnson, Eli Lilly and Company, Abbott Laboratories.

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global non-hodgkin lymphoma treatment market by therapy type, by drug type and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com


Need Assistance


UK : +44 141 628 9353
US : +1 347 709 4931


Contact Sales

What you get

  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included

  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics